The president of Johnson & Johnson, Alex Gorsky, revealed in an interview with financial news media CNBC on the 9th that with the continuous mutation of the new coronavirus, people may have to be vaccinated every year in the future, but the current supply of vaccines is much slower than the demand, and the ratio of the first dose of vaccination completed by people over 65 years old is only slightly more than a quarter, highlighting that The rate of completion of the first dose of vaccine for people over 65 years old is only slightly more than one quarter, highlighting that the vulnerable groups facing the virus are still facing a long wait.
Gorski mentioned in the program that although the vaccines developed at this stage are still effective against variants of the virus in the United Kingdom, South Africa and Brazil, and that the vaccine including the Jolson vaccine maintains 66% effectiveness, he warned that if the virus continues to mutate, the new crown vaccine may follow the pattern of seasonal influenza, which requires annual vaccination.
Gorski said, “Unfortunately, as the virus spreads and as it mutates, and each Time it mutates, it shows us that it has a different impact on the resistance of the antibodies, and the treatment and the vaccine will respond differently.”
Some public health experts fear that the new coronavirus will become endemic, circulating fixedly in population centers, but also with relatively low transmission rates.
Unlike the Pfizer and Moderna vaccines, the Joulsen vaccine does not require a second dose and is not stored in cold temperatures during delivery; in addition, the Joulsen vaccine does not use messenger ribonucleic acid technology (mRNA), but rather uses common cold and flu adenovirus as a vehicle to combine the genetic material of the new coronavirus to pass into the body and trigger an immune response, a technology that was also used in 2019 for use against the Congo’s Ebola virus.
Goldsky said Jolson has increased its vaccine production capacity and is quite confident that it will be able to produce 100 million doses by the end of June: “We will meet our initial commitment, and beyond that we will do everything we can to ensure that we accelerate vaccine production in a safe and effective manner.”
According to the federal Centers for Disease Control and Prevention (CDC), about 28 percent of people aged 75 and older have received at least their first dose of the vaccine, while only 22 percent of seniors aged 65 to 74 have received their first dose; combining the two, only 15.2 million people aged 65 and older have received their first dose of the vaccine.
Tricia Neuman, executive director of the health policy program at the Kaiser Family Foundation, a charitable organization, said, “While state governments have accelerated their efforts to get as many people vaccinated as possible, it’s clear that the supply is still quite limited.”
Recent Comments